Lilly, Novo to Lower Obesity Drug Prices with Trump Deal

Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. President Trump spoke about the deal earlier today from the Oval Office. The companies' products will receive a three-year grace period from Trump's forthcoming duties on pharmaceutical imports and will be available to certain people on Medicare at a lower cost. Bloomberg's Robert Langreth joined Norah Mulinda and Bailey Lipschultz on 'Bloomberg Businessweek Daily' to break it down. (Source: Bloomberg)